Home » FDA Grants Breakthrough Designation to AZ’s Durvalumab
FDA Grants Breakthrough Designation to AZ’s Durvalumab
AstraZeneca has reeled in breakthrough therapy designation for its PD-L1 therapy durvalumab, for the treatment of urothelial bladder cancer.
The treatment caters to patients with PD-L1 positive inoperable or metastatic urothelial bladder cancer whose tumor has progressed during or after one standard platinum-based chemotherapy regimen. Durvalumab also is being studied for first-line bladder cancer treatment as monotherapy, as well as in combination with tremelimumab.
It also is being developed to treat hepatocellular carcinoma and lung, gastric, pancreatic and blood cancers.
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May